
Investigational Agent Achieves All Secondary End Points in Phase 3 Study of Hematologic Malignancies
Omidubicel as treatment of patients with high-risk hematologic malignancies induced rapid platelet engraftment and a reduction in the number of infections and hospitalizations, meeting all 3 secondary end points of a phase 3 clinical trial.








